Large-scale survey says Avastin safe

Article

Off-label intravitreal injections of bevacizumab (Avastin), for the treatment of neovascular and exudative ocular disease, appears to be safe, according to the results of an internet survey published in July issue of the British Journal of Ophthalmology.

Large-scale survey says Avastin safe

Off-label intravitreal injections of bevacizumab (Avastin), for the treatment of neovascular and exudative ocular disease, appears to be safe, according to the results of an internet survey published in July issue of the British Journal of Ophthalmology.

Anne Fung and researchers from Pacific Eye Associates, Bascom Palmer Eye Institute and the Tufts New England Eye Center, United States, created an Internet-based survey designed to identify adverse events (AEs) associated with intravitreal bevacizumab therapy. The survey web address was sent to the international vitreoretinal community via email and rates of AEs were calculated from participant responses.

Off-label use of bevacizumab has been occurring since May 2005 but this is the first large-scale study of adverse events, associated with its use. These short-term results seem to suggest it is a safe treatment option.

Wet AMD costs Europe €3.2 billion per year

Wet age-related macular degeneration (AMD) costs European countries up to €3.2 billion per year, according to a presentation given at the joint meeting of the American Society of Retinal Specialists and European VitreoRetinal Society in Cannes, France.

The results showed that those with AMD require assistance with everyday activities at a rate of four times greater than those without the disease (29% vs. 7%) and are twice as likely to fall, requiring medical assistance (16% vs. 8.3%). The study also found that the direct and indirect costs related to the care and treatment of those with AMD varied by country but were always significantly higher than those incurred by the control group.

Professor Soubrane concluded by remarking that the economic burden of caring for those with wet AMD could be eased through earlier detection and improved access to new, effective treatments.

AMD genes identified

Researchers have discovered a way to more accurately identify those at risk of developing age-related macular degeneration (AMD).

A study conducted at Queen's University, Belfast, Northern Ireland, found that people with a deletion of two key genes have a lower risk of developing AMD. It is hoped that this research may help in the development of a preventative treatment based on gene silencing.

The bioptics advantage

Reverse bioptics with phakic intraocular lenses (IOLs) or refractive lens exchange can be successfully used to correct regressed corneal surgery, according to the results of a review published in the August issue of Current Opinion in Ophthalmology.

Antonio Leccisotti of the Ophthalmic Surgery Unit, Casa di Cura Rugani, Siena, Italy, conducted a review of the most recent research into bioptics. His research suggested that, in myopia and hyperopia, bioptics with phakic IOLs or refractive lens exchange and subsequent excimer laser treatment offer a similar safety profile and improved predictability compared with sole IOL surgery, with complications relating mainly to the IOLs. With regards to keratoconus and pellucid marginal degeneration, intracorneal rings have been successfully combined with phacoemulsification or with phakic IOLs in just a limited number of eyes.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.